Minia Campos‐Domínguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Minia Campos‐Domínguez has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Torrelo
Department of Dermatology Hospital Infantil Universitario Niño Jesús Madrid Spain
3 shared publications Angela Hernández‐Martín
Department of Dermatology, Hospital Infantil Niño Jesús, Madrid, Spain
2 shared publicationsAntonio Torrelo
Department of Dermatology University Children's Hospital Niño Jesús Madrid Spain
2 shared publications- Belén Rodríguez-Sánchez
Department of Dermatology Hospital General Universitario Gregorio Marañón Madrid Spain
2 shared publications Cristina Beléndez‐Bieler
Department of Pediatrics Hospital General Universitario Gregorio Marañón Madrid Spain
2 shared publicationsGloria Garnacho‐Saucedo
Dermatology Department Hospital Universitario Reina Sofía Córdoba Spain
2 shared publications
Latest Publications
- 19 February 2026
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (3) , 743-745
Peculiar Phenotype of Linear Prepubertal Hidradenitis Suppurativa Associated With Trisomy 13: Report of Two Clinical Cases
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that typically affects intertriginous areas and is rarely associated with chromosomal abnormalities. This report describes two pediatric cases of HS‐like lesions overlying phylloid pigmentary mosaicism, both associated with mosaic trisomy 13. The first case involves a 5‐year‐old girl with developmental anomalies and comedonal lesions localized to areas of pigmentary mosaicism, confirmed by skin biopsy showing 30% aneuploid cells with full trisomy 13. The second case is a 15‐month‐old girl who developed follicular lesions years later overlying a hypopigmented mosaic patch; genetic analysis of skin tissue revealed 50% aneuploid cells with partial trisomy 13. These cases support an emerging link between mosaic trisomy 13 and follicular occlusion disorders, including HS. The involvement of chromosome 13 genes, such as GJB2 (connexin 26), may play a role in the pathogenesis.
- 19 February 2026
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (3) , 743-745
Peculiar Phenotype of Linear Prepubertal Hidradenitis Suppurativa Associated With Trisomy 13: Report of Two Clinical Cases
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that typically affects intertriginous areas and is rarely associated with chromosomal abnormalities. This report describes two pediatric cases of HS‐like lesions overlying phylloid pigmentary mosaicism, both associated with mosaic trisomy 13. The first case involves a 5‐year‐old girl with developmental anomalies and comedonal lesions localized to areas of pigmentary mosaicism, confirmed by skin biopsy showing 30% aneuploid cells with full trisomy 13. The second case is a 15‐month‐old girl who developed follicular lesions years later overlying a hypopigmented mosaic patch; genetic analysis of skin tissue revealed 50% aneuploid cells with partial trisomy 13. These cases support an emerging link between mosaic trisomy 13 and follicular occlusion disorders, including HS. The involvement of chromosome 13 genes, such as GJB2 (connexin 26), may play a role in the pathogenesis.
- Open Access
- 15 February 2026
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 69 (2) , 182-185
Happle-Tinschert syndrome in an infant: clinical, radiologic and genetic correlation
Happle-Tinschert syndrome (HTS) is a rare mosaic disorder characterized by segmental basaloid follicular hamartomas (BFH) and variable multisystem involvement, including skeletal, dental, and occasional neurologic abnormalities. 1-5) Although cutaneous findings often prompt initial evaluation, the condition is clinically relevant to pediatricians because growth-plate abnormalities can evolve silently and cause progressive deformities throughout childhood. 3,4) Early recognition, targeted genetic testing of affected tissue, and multidiscipli nary follow-up are essential for adequate care. HTS belongs to the mosaic hedgehog-pathway spectrum, which also includes Curry-Jones syndrome and segmental basal cell nevus syndrome. These entities arise from
- 15 February 2026
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 69 (2) , 182-185
Open AccessHapple-Tinschert syndrome in an infant: clinical, radiologic and genetic correlation
Happle-Tinschert syndrome (HTS) is a rare mosaic disorder characterized by segmental basaloid follicular hamartomas (BFH) and variable multisystem involvement, including skeletal, dental, and occasional neurologic abnormalities. 1-5) Although cutaneous findings often prompt initial evaluation, the condition is clinically relevant to pediatricians because growth-plate abnormalities can evolve silently and cause progressive deformities throughout childhood. 3,4) Early recognition, targeted genetic testing of affected tissue, and multidiscipli nary follow-up are essential for adequate care. HTS belongs to the mosaic hedgehog-pathway spectrum, which also includes Curry-Jones syndrome and segmental basal cell nevus syndrome. These entities arise from
- 20 November 2025
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (2) , 289-299
Post‐Hematopoietic Stem Cell Transplantation Eczematous Dermatitis Spectrum Successfully Treated With Dupilumab: A Case Series and Review of the Literature
Background: Hematopoietic stem cell transplantation (HSCT) is associated with several dermatological adverse events, including the de novo onset of pruritus and eczema. Some authors consider this a variant of graft‐versus‐host disease (GvHD) and refer to it as eczematous or atopic dermatitis (AD)‐like GvHD, while others categorize it separately as eczematous or AD‐like dermatitis. This study aimed to report a pediatric case series and review previously published cases treated with dupilumab. Methods: Retrospective multicenter study including patients aged 0–18 treated with dupilumab for new eczematous lesions following HSCT up to 2024 in three tertiary hospitals in Spain. A literature review in PubMed identified all reported pediatric and adult cases. Results: A total of 24 cases were identified: 9 from our centers and 15 from the literature. Median onset was 3 months post‐HSCT. All patients presented with pruritus and eczema. 47% showed flexural involvement. Histology revealed eczematous features in 73%, mixed GvHD/eczema in 20%, and pure GvHD in 7%. 38% were classified as post‐HSCT eczema, and 63% as eczematous or AD‐like GvHD. All were refractory to topical corticoids and different systemic immunosuppressants. Dupilumab led to complete or near‐complete resolution in 96% of cases. No serious adverse events were reported. Conclusion: Dupilumab appears to be effective and safe for eczematous lesions occurring after HSCT, regardless of whether the histopathological characteristics align with eczema or GvHD. This supports a shared spectrum between eczematous dermatitis and GvHD, and the use of a neutral diagnostic term. Further research is needed to clarify its pathogenesis.
- 20 November 2025
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (2) , 289-299
Post‐Hematopoietic Stem Cell Transplantation Eczematous Dermatitis Spectrum Successfully Treated With Dupilumab: A Case Series and Review of the Literature
Background: Hematopoietic stem cell transplantation (HSCT) is associated with several dermatological adverse events, including the de novo onset of pruritus and eczema. Some authors consider this a variant of graft‐versus‐host disease (GvHD) and refer to it as eczematous or atopic dermatitis (AD)‐like GvHD, while others categorize it separately as eczematous or AD‐like dermatitis. This study aimed to report a pediatric case series and review previously published cases treated with dupilumab. Methods: Retrospective multicenter study including patients aged 0–18 treated with dupilumab for new eczematous lesions following HSCT up to 2024 in three tertiary hospitals in Spain. A literature review in PubMed identified all reported pediatric and adult cases. Results: A total of 24 cases were identified: 9 from our centers and 15 from the literature. Median onset was 3 months post‐HSCT. All patients presented with pruritus and eczema. 47% showed flexural involvement. Histology revealed eczematous features in 73%, mixed GvHD/eczema in 20%, and pure GvHD in 7%. 38% were classified as post‐HSCT eczema, and 63% as eczematous or AD‐like GvHD. All were refractory to topical corticoids and different systemic immunosuppressants. Dupilumab led to complete or near‐complete resolution in 96% of cases. No serious adverse events were reported. Conclusion: Dupilumab appears to be effective and safe for eczematous lesions occurring after HSCT, regardless of whether the histopathological characteristics align with eczema or GvHD. This supports a shared spectrum between eczematous dermatitis and GvHD, and the use of a neutral diagnostic term. Further research is needed to clarify its pathogenesis.
- 22 February 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (5) , 940-942
Vulvar erosions in a young girl
- 22 February 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (5) , 940-942
Vulvar erosions in a young girl
- Open Access
- 3 January 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 98 (3) , 391-394
Kaposiform hemangioendothelioma and tufted angioma: two entities of the same clinicopathological spectrum
- 3 January 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 98 (3) , 391-394
Open AccessKaposiform hemangioendothelioma and tufted angioma: two entities of the same clinicopathological spectrum
- 3 May 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 39 (4) , 557-562
Inter‐ and intra‐observer variability in the selection of therapy for infantile hemangiomas among pediatric dermatologists in Spain
Background: Guidelines and expert recommendations on infantile hemangiomas (IH) are aimed at increasing homogeneity in clinical decisions based on the risk of sequelae.Objective: The objective was to analyze the inter‐ and intra‐observer agreement among pediatric dermatologists in the choice of treatment for IH.Methods: We performed a cross‐sectional inter‐rater and intra‐rater agreement study within the Spanish infantile hemangioma registry. Twenty‐seven pediatric dermatologists were invited to participate in a survey with 50 clinical vignettes randomly selected within the registry. Each vignette contained a picture of an infantile hemangioma with a clinical description. Raters chose therapy among observation, topical timolol, or oral propranolol. The same survey reordered was completed 1 month later to assess intra‐rater agreement. Vignettes were stratified into hemangioma risk categories following the Spanish consensus on IH. The agreement was measured using kappa statistics appropriate for the type of data (Gwet's AC1 coefficient and Gwet's paired t test).Results: Twenty‐four dermatologists completed the survey. Vignettes represented 7.8% of the Spanish hemangioma registry. The inter‐rater agreement on the treatment decision was fair (AC1 = 0.39, 95% confidence interval [CI]: 0.30–0.47). When stratified by risk category, good agreement was reached for high‐risk hemangiomas (AC1 = 0.77, 95% CI: 0.51–1.00), whereas for intermediate‐ and low‐risk categories, the agreement was only fair (AC1 0.31, 95% CI: 0.16–0.46 and AC1 = 0.38, 95% CI: 0.27–0.48, respectively). Propranolol was the main option for high‐risk hemangiomas (86.4%), timolol for intermediate‐risk (36.8%), and observation for low‐risk ones (55.9%). The intra‐rater agreement was good. The inter‐rater agreement between pediatric dermatologists on the treatment of IH is only fair. Variability was most significant with intermediate‐ and low‐risk hemangiomas.
- 3 May 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 39 (4) , 557-562
Inter‐ and intra‐observer variability in the selection of therapy for infantile hemangiomas among pediatric dermatologists in Spain
Background: Guidelines and expert recommendations on infantile hemangiomas (IH) are aimed at increasing homogeneity in clinical decisions based on the risk of sequelae.Objective: The objective was to analyze the inter‐ and intra‐observer agreement among pediatric dermatologists in the choice of treatment for IH.Methods: We performed a cross‐sectional inter‐rater and intra‐rater agreement study within the Spanish infantile hemangioma registry. Twenty‐seven pediatric dermatologists were invited to participate in a survey with 50 clinical vignettes randomly selected within the registry. Each vignette contained a picture of an infantile hemangioma with a clinical description. Raters chose therapy among observation, topical timolol, or oral propranolol. The same survey reordered was completed 1 month later to assess intra‐rater agreement. Vignettes were stratified into hemangioma risk categories following the Spanish consensus on IH. The agreement was measured using kappa statistics appropriate for the type of data (Gwet's AC1 coefficient and Gwet's paired t test).Results: Twenty‐four dermatologists completed the survey. Vignettes represented 7.8% of the Spanish hemangioma registry. The inter‐rater agreement on the treatment decision was fair (AC1 = 0.39, 95% confidence interval [CI]: 0.30–0.47). When stratified by risk category, good agreement was reached for high‐risk hemangiomas (AC1 = 0.77, 95% CI: 0.51–1.00), whereas for intermediate‐ and low‐risk categories, the agreement was only fair (AC1 0.31, 95% CI: 0.16–0.46 and AC1 = 0.38, 95% CI: 0.27–0.48, respectively). Propranolol was the main option for high‐risk hemangiomas (86.4%), timolol for intermediate‐risk (36.8%), and observation for low‐risk ones (55.9%). The intra‐rater agreement was good. The inter‐rater agreement between pediatric dermatologists on the treatment of IH is only fair. Variability was most significant with intermediate‐ and low‐risk hemangiomas.
- Open Access
- 19 April 2022
- Published by Georg Thieme Verlag KG in European Journal of Pediatric Surgery Reports
- Vol. 10 (01) , e25-e29
Juvenile Xanthogranuloma as Differential Diagnosis of a Vulvar Mass: A Case Report
Vulvar masses in children are an unusual finding but their differential diagnosis is extensive. In case of solid masses, rhabdomyosarcoma (RMS) must always be considered due to the fact that it is the most common tumor in external genitals during childhood. However, RMS has a radiological appearance very similar to juvenile xanthogranuloma (JXG). We present a 16-month-old girl with a 2 cm solid mass on her left labia majora, with four overlying cutaneous papules. After imaging tests, an excisional biopsy was programmed due to high malignancy suspicion. Histopathology of the mass and one of the papules was diagnostic for JXG. After a 12-month follow-up, the patient shows no signs of relapse or complication. Deep JXG is an uncommon entity in childhood and exceptional in the genital area. Therefore, it must be included in the differential diagnosis of a solid vulvar mass, especially if accompanying yellowish xanthomatous cutaneous lesions are present.
- 19 April 2022
- Published by Georg Thieme Verlag KG in European Journal of Pediatric Surgery Reports
- Vol. 10 (01) , e25-e29
Open AccessJuvenile Xanthogranuloma as Differential Diagnosis of a Vulvar Mass: A Case Report
Vulvar masses in children are an unusual finding but their differential diagnosis is extensive. In case of solid masses, rhabdomyosarcoma (RMS) must always be considered due to the fact that it is the most common tumor in external genitals during childhood. However, RMS has a radiological appearance very similar to juvenile xanthogranuloma (JXG). We present a 16-month-old girl with a 2 cm solid mass on her left labia majora, with four overlying cutaneous papules. After imaging tests, an excisional biopsy was programmed due to high malignancy suspicion. Histopathology of the mass and one of the papules was diagnostic for JXG. After a 12-month follow-up, the patient shows no signs of relapse or complication. Deep JXG is an uncommon entity in childhood and exceptional in the genital area. Therefore, it must be included in the differential diagnosis of a solid vulvar mass, especially if accompanying yellowish xanthomatous cutaneous lesions are present.
- Open Access
- 1 April 2022
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 113 (4) , 432-434
Fibromatosis digital infantil: primum non nocere
- 1 April 2022
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 113 (4) , 432-434
Open AccessFibromatosis digital infantil: primum non nocere
- 24 January 2021
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (2) , 530-532
Ectodermal dysplasia with congenital adermatoglyphia (Basan syndrome): Report of two cases presenting with extensive congenital milia
Basan syndrome is a rare autosomal dominant genodermatosis, characterized by rapidly healing congenital acral bullae, congenital milia and adermatoglyphia (lack of finger and toeprints). This type of ectodermal dysplasia has been infrequently reported in the literature. A pathogenic mutation in the SMARCAD1 gene has been demonstrated to cause this rare disorder.
- 24 January 2021
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (2) , 530-532
Ectodermal dysplasia with congenital adermatoglyphia (Basan syndrome): Report of two cases presenting with extensive congenital milia
Basan syndrome is a rare autosomal dominant genodermatosis, characterized by rapidly healing congenital acral bullae, congenital milia and adermatoglyphia (lack of finger and toeprints). This type of ectodermal dysplasia has been infrequently reported in the literature. A pathogenic mutation in the SMARCAD1 gene has been demonstrated to cause this rare disorder.
- 2 October 2020
- Published by Springer Nature in European Journal of Plastic Surgery
- Vol. 44 (4) , 543-548
Successful treatment of giant lymphatic malformation with symptomatic cutaneous vesicles by surgical excision and coverage with Integra®
- 2 October 2020
- Published by Springer Nature in European Journal of Plastic Surgery
- Vol. 44 (4) , 543-548
Successful treatment of giant lymphatic malformation with symptomatic cutaneous vesicles by surgical excision and coverage with Integra®